Obermatt
See Similar Stocks →

ImmuCell

NAQ:ICCC · US4525253062
BiotechnologySmall

360

73
Medium confidence — indicative
Profit price1
Owner Earnings Yield87
Dividend Yield1
Price/Sales89
EV / Gross Profit50
Price/Book60
Return on Capital88
Cash Return on Capital100
Return on Equity90
EBIT Margin91
Gross Profitability74
Accruals42
Owner Earnings Margin95
Sales growth76
Profit growth7
Reinvestment65
Price momentum49
Debt load38
Refinancing93
Debt Payback50
Liquidity92
Analyst ratings—
Expectations trend—
Market mood38
Value Creation10/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

ImmuCell clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryUSA
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQCM
Founded1982
Employees23
Websiteimmucell.com
ISINUS4525253062
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
Animal FeedLivestockHealth DiagnosticsVaccinesEmployee BenefitsInnovation ManagementManufacturing

Description

ImmuCell Corporation operates as an animal health company. After achieving approval from the Center for Veterinary Biologics, U.S. Department of Agriculture (USDA) to sell First Defense in 1991, the company focused most of its efforts during the 199…

Analysis

Quality compounder

ImmuCell Corporation is a quality compounder: a well-run business trading at a price that reflects what it is worth. One caution: reported profits have recently run ahead of actual cash, which we track closely.

The price is expensive. You pay 93.7× its owner earnings: the cash an owner could take out each year, which is in the historically expensive zone.

The trajectory is moderate and the balance sheet is adequate. The company scores 10/20 on our value-creation score: creating some value.

What to watch: Some accounting patterns deserve a closer look. Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
87
2026

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
89
—
—
—
Price/Earnings
—
—
—
—
Price/Book
60
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
82
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare ImmuCell with its peers
Madrigal Pharmaceuticals
NSQ:MDGL
67
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
Natera
NSQ:NTRA
39
CountryUSA
IndustryBiotechnology
SizeLarge
Full Stock Analysis →
Scholar Rock
NSQ:SRRK
67
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Myriad Genetics
NSQ:MYGN
12
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
Invivyd
NMQ:IVVD
40
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Avidity Biosciences
NMQ:RNA
28
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →